Feed AVTX
AV

Avalo Therapeutics, Inc. AVTX · NASDAQ

$12.26 -0.81% (-$0.10)

Market cap
$657.5M
Enterprise value
$572.4M
P/E
-
Forward P/E
-
PEG
-
P/S
11,144.1x
P/FCF
-
EV/EBITDA
-
ROIC
-19.5%
Bruto marža
-16,861.0%
Neto marža
-170,056.0%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
0.79
Free float
89.6%

O podjetju

Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.

Sector

Healthcare

Industry

Biotechnology

CEO

Garry A. Neil

Employees

33

Headquarters

Wayne

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.